a Rosh PharmaThrough molecular engineering and biotechnological innovations, it advances the goal of better meeting the needs of people with retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME). The region received R$33 million in investment Only in clinical studies since 2018, and more than R$10 million moved into the country last year. The company already has solutions for ophthalmology Certified in more than 50 countries including the United States, Japan and the United Kingdom.
Since the beginning of the studies until last year, the company has increased the pace of investment in the region by 96%. “Roche has a long-term commitment to access to medical innovations and we are excited about the arrival of an area essential to the health of Brazilians. Our commitment to clinical research permeates all of our work and is reflected in results. In 2022, Roche Farma has invested more than R$440 million in clinical research in the country, An increase of more than 30% compared to 2021, accelerating access to innovation in Brazil”, says Michele Fabian, Medical Lead at Roche Farma Brasil.
In Brazil, wet AMD and DME are expected to affect 1.7 million people over the next five years. Together, these two diseases are the leading causes of vision loss and today affect about 40 million people worldwide, who require treatment with regular intraocular injections. “We believe in a new era of ophthalmology, marked by the development of new molecules and technologies that help reduce the limitations that retinal diseases can cause. This will allow us to build the future of ophthalmology by setting a new standard for treating these diseases and improving patients’ quality of life and support network.”
